Editorial Comment on: Laparoscopic Retroperitoneal Lymph Node Dissection: Does It Still Have a Role in the Management of Clinical Stage I Nonseminomatous Testis Cancer? A European Perspective

摘要

Surgical staging in patients with clinical stage I nonseminomatous germ cell tumors (NSGCT) has become a rare recommendation. In Europe, the recommendation is for patients to undergo a risk-adapted treatment with surveillance forlow-risk tumors (no vascular invasion) and chemotherapy for high-risk tumors . In Canada, the options for this patient group include surveillance, even for patients with high-risk features, based on equal cancer-specific survival data of >98% . In view of these management guidelines, the review of Rassweiler and colleagues is important for this small subgroup of <10% of patients with NSGCT who (1) wish to be staged surgically; (2) have pure teratomatous tumors; and (3) are at high risk for recurrence, do not want to undergo surveillance, and have contraindications for chemotherapy.